Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Hot Longevity Mandate: Europe-Based Venture Fund

3 May

The firm is a venture capital firm founded in 2020 and is headquartered in Paris, France, with an additional office based in the USA. The firm is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities, but focuses on USA and Europe-based companies.

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic, but tend to stray away from cardiovascular and CNS indications.

The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: USA-based Corporate Venture Capital with Flexible Check Size Interested in Digital Health and Diagnostics

2 May

A corporate venture firm founded in 2020 is headquartered in Denver, Colorado. The firm’s typical check size ranges from $1-10M in Seed stage and beyond, with Series A being their sweet spot. Because of the flexibility in their balance sheet and investment committee, the firm has also looked at investments greater than $10M in Series C and D companies. The firm typically makes equity investments but has used notes for later stage investments. The firm is USA focused but will look at companies headquartered elsewhere if there’s USA commercial traction or intent to commercialize in the US.

The firm is interested in diagnostic and digital health sectors and is open to all subsectors and indications. The firm is not interested in therapeutics or medical devices, unless they’re noninvasive medical devices. The firm is especially interested in technology that impacts their polychronic patients, especially since the firm has a strong intention of moving upstream into the CKD and ESKD space. The firm has done a lot of work in the cardiometabolic and comorbidity space, more specifically looking at technology for cardiovascular disease, diabetes, COPD, social determinants of health, end of life and behavioral health.

The firm prefers management teams with entrepreneurial experience but is open to all types of management teams and has backed first-time founders. For companies not in the diagnostics or device space, The firm likes to see at least $1M in ARR. The firm has led in the past but prefers to join syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The Power of Capital Investors and Licensing Partners Data

28 Apr

By Rory McCann, Marketing Manager & Conference Producer, LSN

Launching a successful startup requires data. Life science entrepreneurs know the value of data when pitching to investors, but those investor meetings don’t happen without a well-curated dataset and global target list (GTL). In a recent conversation with Life Science Nation (LSN) business development manager Alex Vassallo, we discussed how fundraising founders can source a GTL of investors and strategic partners who are a fit for their product and stage of development using the LSN Investor Database, and how to use this tool in conjunction with tried-and-true principles of successful partnering.

Contact us to learn more about the LSN Investor Database, view a demo, and discuss how our products and services can help your early-stage fundraise.

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Alexander Vassallo
Manager of Business Development
Book a Meeting
Email Me

Last Chance to Pitch!

28 Apr

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireThere are still pitching slots available for Digital RESI, June 7-9! The deadline for the Innovator’s Pitch Challenge (IPC) is tomorrow, April 29. The IPC is a great opportunity to showcase your company and stand out among RESI’s community of investors and strategic partners. A recent IPC winner spoke with our team to share their process as a first-time RESI attendee and pitching company. Check out Bold Therapeutics’ interview here.

The IPC includes unique benefits to maximize your pitching experience:

  • Dedicated Webpage: Each IPC finalist company will have their own dedicated landing page, which will include a short pitch video, slide deck, executive summary, and other marketing collateral they wish to highlight that is relevant to their company.
  • Enhanced Visibility: The RESI live agenda will open a few days prior to the conference for judges and attendees to review finalist company materials. The agenda will remain live for a month following the event.
  • Live Q&A: IPC finalists are grouped with other companies based on sector and technology and will be assigned to a one-hour Q&A session with a panel of investors and industry experts who actively invest in and work with similar technology. All judges are instructed to review pitch videos before the session, enabling them to ask more targeted, high-level questions. After the session is over, IPC finalists are connected with participating investors via email.

The IPC has grown into one of RESI’s most popular and valuable features. The deadline to apply is tomorrow, Friday, April 29.

*A one-day or three-day registration + $800 pitch fee are required to participate.

Fulbright Scholars Learn to Fly with Life Science Nation

28 Apr

By Alexander Vassallo, Manager of Business Development West Coast (US), LSN

“If I told you to jump out of an airplane without a parachute, would you do it?”

This was not the first question that the Fulbright scholars attending the Boston seminar were expecting to receive, but after a 3-day entrepreneurial masterclass workshop delivered by Life Science Nation (LSN), it was a question all the scholars had an answer to. Starting a company is one of the most difficult tasks an entrepreneur can undertake, however, with the right mindset and genuine entrepreneurial agency, your chances of success can greatly improve.

The Fulbright Commission invited LSN to help equip the next generation of aspiring scientist-entrepreneurs with some of the skills they would need to be industry leaders in the life science arena. Led by LSN Founder and CEO, Dennis Ford, alongside the VP of Business Development, Candice He, and the BD Manager for the West Coast, Alex Vassallo, the Boston Fulbright seminar, April 21-23, was an engaging experience that this year’s cohort of scholars would not soon forget.

Participants were given an opportunity to explore and examine the process of taking life-saving inventions from ideation and creation stages to the public market. The life science domain is unique in that a startup entity’s journey starts with academic tech transfer agreements, which lead to regional and national government non-dilutive funding followed by capital investors and licensing partners. This entrepreneurial masterclass highlighted the core elements of launching an early-stage company’s branding and messaging in conjunction with a global partnering campaign. The theme of the workshop was finding your entrepreneurial voice, developing a compelling narrative, and then clearly telling the story of team, product, company milestones, and partnering strategy.

The 3-day entrepreneurial workshop concluded with an impressive pitch competition that highlighted not only the talent and entrepreneurial agency that the Fulbright scholars possessed, but that the key take-home messages of the masterclass had been well integrated and understood. We can expect many of these students to be industry leaders in the coming years and were honored to be a part of their journey. Whilst starting a company in many ways is comparable to jumping out of an airplane without a parachute, the scholars of the Fulbright Commission are taking the plunge.

Who’s Getting Funded?

21 Apr

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Life Science Nation (LSN) has built a funding superstructure over the past decade, but what is the true metric of success in the complex early-stage life science ecosystem? The number of companies funded, and the amount allocated are terrific metrics, but when consumed as comprehensive and independent of context, this data can be misleading and unhelpful. Let’s dive into LSN’s tracking of these companies and discuss the value this data holds and how it can work for you.

As previously mentioned, LSN tracks companies funded in part through participating at the Redefining Early Stage Investment (RESI) partnering conferences, subscribing to the LSN Investor Database, or using our Branding, Messaging and Matching services. The organic nature of partnering, along with its typical 9–18-month timeline, makes it challenging to track and verify, therefore, this data is typically self-reported by our partners and verified through public press releases. As such, we estimate this list makes up only about a third of these deals with LSN as part of the strategy, as many cannot be publicly disclosed. The funded partner list consists of nearly 85 startups across early-stage life science and healthcare with deals valuing more than $1.3B that have used LSN’s products and services as part of the campaign strategy. Check out the basic structure of these deals below:

Chart-1

From the data, we see that the 4Ds (Drugs, Devices, Diagnostics, and Digital Health) that LSN focuses on are broadly represented in the number of companies that receive funding, but they are not the only companies that investors are pursuing. Additionally, therapeutics leads the pack, despite the reputation that pre-clinical, early-stage therapeutics are too great a risk for investors to jump into. Learn more about that in our recent interviews with RESI Innovator’s Pitch Challenge winners: OncoXome CEO, Auriane Gamelin and Prolifagen CEO, Claudine Bruck.

Chart-2

We see that early-stage deal flow is alive and well in the life sciences, but not all capital is the same. Know what you want but keep an open mind when meeting with relevant and knowledgeable partners who are a fit for you. Early-stage fundraising is a critical point in a startup’s development and growth, but these partnerships will last beyond the round and will play a large part in bringing your company forward.

The tools LSN offers are powerful, but what these funded companies also have in common is leg work. LSN helps companies build their global target list of capital investors and licensing partners through services, data, and events, but it’s the founders and their stories that shine in those meetings. Every successful raise has dedicated, hard-working, creative, and resourceful founders and team members doing research, booking meetings, and pitching to investors who are a fit for their product and stage of development. LSN has long provided guidance and resources to help entrepreneurs, but it’s their own work that gets them over the finish line.

Has LSN played a role in your fundraising or investing? Tell us your story! We want to add your deal to our list and share what you have learned throughout the process. If you’re interested in learning more about what LSN can help you achieve in your own global fundraising campaign, connect with our business development team!

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Alexander Vassallo
Manager of Business Development
Book a Meeting
Email Me

What’s New for Tech Hubs at RESI?

21 Apr

By Erika Wu, Business Development Manager, Global Tech Hub, LSN

At the Redefining Early Stage Investments (RESI) conferences, tech hubs represent a global ecosystem of accelerators, incubators, non-profits, universities, and regional and government organizations who set up their early-stage life science startups for success with their entrepreneurship journey. RESI has hosted tech hubs ranging from National Institute of Aging (NIA), Lyon Biopole, IntuitiveX, University of British Columbia, and more.

Through RESI partnership, tech hub constituents gain access to resources beyond partnering, such as Life Science Nation (LSN)’s Investor Database, the Innovator’s Pitch Challenge (IPC), and free workshops to help develop strong relationships with investors and secure necessary early-stage funding.

This year, LSN has developed updated and personalized programs to further benefit tech hubs and their constituents. Check out a preview of our updated 2022 programs to promote tech hub involvement and accelerate growth of each individual constituent. Each option is available for tech hubs to take advantage of to add value to their constituents who raised less than $2M:

For Tech Hub Constituents:

  • 50% discount for constituent registration at any virtual or hybrid RESI conference (constituent must be from LSN’s tech hub partners)
  • Group Fundraising Database Package (3 companies minimum):
    • 4-month access to the Investor Database
    • Free constituent registration + pitching slot at any virtual or hybrid RESI conference

For Tech Hub Staff:

  • Bronze Sponsorship ($2,500 annually):
    • Free tech hub staff registration at any virtual or hybrid RESI conference
    • 50% discount for constituent registration at any virtual or hybrid RESI conference
    • Dedicated pitch session
    • Exhibition slot

If you’re a member of a tech hub or looking to add value to your members, reach out to see which offerings best fit your needs. From lab to clinic, and providers to patients, LSN is accelerating the growth and success of companies emerging from tech hubs. Schedule a meeting with Erika Wu, Business Development Manager, Global Tech Hub at Life Science Nation.

← Older Entries
Newer Entries →